S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
S&P 500   3,141.63 (+0.29%)
DOW   27,911.30 (+0.11%)
QQQ   204.98 (+0.53%)
AAPL   270.77 (+0.85%)
FB   202.26 (+0.69%)
MSFT   151.70 (+0.38%)
GOOGL   1,344.25 (+0.10%)
AMZN   1,748.72 (+0.55%)
CGC   20.25 (+0.80%)
NVDA   217.34 (+1.57%)
MU   49.26 (+3.79%)
BABA   204.64 (+2.09%)
GE   10.97 (-0.36%)
TSLA   352.70 (+1.11%)
T   38.17 (+0.29%)
AMD   39.47 (+0.08%)
ACB   2.45 (-2.78%)
F   9.11 (+0.44%)
PRI   135.45 (+0.13%)
NFLX   298.93 (+1.98%)
BAC   33.64 (+0.33%)
GILD   67.78 (+1.04%)
DIS   147.59 (+1.02%)
Log in

NYSE:BMY - Bristol-Myers Squibb Stock Price, Forecast & News

$62.41
+0.32 (+0.52 %)
(As of 12/11/2019 04:00 PM ET)
Today's Range
$61.96
Now: $62.41
$62.98
50-Day Range
$54.27
MA: $57.48
$62.38
52-Week Range
$42.48
Now: $62.41
$62.98
Volume18.26 million shs
Average Volume16.20 million shs
Market Capitalization$101.68 billion
P/E Ratio15.68
Dividend Yield2.64%
Beta0.7
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP11012210
Phone212-546-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.56 billion
Cash Flow$4.56 per share
Book Value$8.65 per share

Profitability

Net Income$4.92 billion

Miscellaneous

Employees23,300
Outstanding Shares1,629,285,000
Market Cap$101.68 billion
Next Earnings Date1/23/2020 (Estimated)
OptionableOptionable

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.


Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 5th. Investors of record on Friday, January 3rd will be paid a dividend of $0.45 per share on Monday, February 3rd. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.88%. The ex-dividend date of this dividend is Thursday, January 2nd. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.41. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) released its quarterly earnings results on Thursday, October, 31st. The biopharmaceutical company reported $1.17 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.06 by $0.11. The biopharmaceutical company earned $6.01 billion during the quarter, compared to analyst estimates of $5.89 billion. Bristol-Myers Squibb had a net margin of 23.53% and a return on equity of 45.49%. The business's revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the business posted $1.09 earnings per share. View Bristol-Myers Squibb's Earnings History.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, January 23rd 2020. View Earnings Estimates for Bristol-Myers Squibb.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY19 earnings guidance on Thursday, October, 31st. The company provided earnings per share (EPS) guidance of $4.25-4.35 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.29.

What price target have analysts set for BMY?

16 brokerages have issued 1 year price objectives for Bristol-Myers Squibb's stock. Their forecasts range from $46.36 to $66.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $58.31 in the next twelve months. This suggests that the stock has a possible downside of 6.6%. View Analyst Price Targets for Bristol-Myers Squibb.

What is the consensus analysts' recommendation for Bristol-Myers Squibb?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bristol-Myers Squibb.

Has Bristol-Myers Squibb been receiving favorable news coverage?

Media stories about BMY stock have been trending somewhat negative recently, according to InfoTrie. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Bristol-Myers Squibb.

Are investors shorting Bristol-Myers Squibb?

Bristol-Myers Squibb saw a drop in short interest in November. As of November 29th, there was short interest totalling 97,220,000 shares, a drop of 35.7% from the November 14th total of 151,230,000 shares. Based on an average trading volume of 16,520,000 shares, the short-interest ratio is presently 5.9 days. Approximately 6.0% of the shares of the stock are sold short. View Bristol-Myers Squibb's Current Options Chain.

Who are some of Bristol-Myers Squibb's key competitors?

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), Chicago Bridge & Iron (CBI), AT&T (T), Diebold Nixdorf (DBD), Bank of America (BAC), Pfizer (PFE), General Electric (GE), Intel (INTC), Verizon Communications (VZ) and Alibaba Group (BABA).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 54)
  • Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
  • Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
  • Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
  • Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include State Street Corp (4.21%), Sumitomo Mitsui Trust Holdings Inc. (0.45%), California Public Employees Retirement System (0.38%), Parametric Portfolio Associates LLC (0.28%), California State Teachers Retirement System (0.17%) and Rhumbline Advisers (0.17%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini, Theodore R Samuels II and Thomas J Jr Lynch. View Institutional Ownership Trends for Bristol-Myers Squibb.

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Worldquant Millennium Advisors LLC, Man Group plc, Massachusetts Financial Services Co. MA, State of New Jersey Common Pension Fund D, State of Tennessee Treasury Department, Envestnet Asset Management Inc., AMF Pensionsforsakring AB and Pictet Asset Management Ltd.. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include John E Elicker, Karen Murphy Santiago and Louis S Schmukler. View Insider Buying and Selling for Bristol-Myers Squibb.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was purchased by a variety of institutional investors in the last quarter, including Railway Pension Investments Ltd, PGGM Investments, California Public Employees Retirement System, Phoenix Holdings Ltd., Redmile Group LLC, Berkshire Asset Management LLC PA, Teacher Retirement System of Texas and Parametric Portfolio Associates LLC. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $62.41.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $101.68 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.92 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe.View Additional Information About Bristol-Myers Squibb.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is http://www.bms.com/.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]


MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  974 (Vote Outperform)
Underperform Votes:  890 (Vote Underperform)
Total Votes:  1,864
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Neutral Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel